Question 1

When did Novo Nordisk say the UK MHRA approved Wegovy®pill?

Accepted Answer

Novo Nordisk said the UK Medicines and Healthcare products Regulatory Agency approved Wegovy®pill on 12 June 2026, making it the first daily GLP‑1 weight‑loss tablet licensed in the UK and the MHRA the third regulator to license it after the US FDA and the United Arab Emirates.

Question 2

Does Novo Nordisk say oral semaglutide has any cardiovascular approvals?

Accepted Answer

Novo Nordisk states the oral semaglutide therapy carries a major adverse cardiovascular events (MACE) risk‑reduction approval in some jurisdictions.

Question 3

What recurring themes do broker notes and market commentary highlight for Novo Nordisk?

Accepted Answer

Broker notes and market commentary consistently highlight the sustainability of GLP-1 drug demand (volume vs one‑off spikes), competitive dynamics from new entrants and alternatives, pricing and reimbursement developments across key markets, and the impact of these factors on margins and guidance.

Question 4

What did Novo Nordisk report for once-daily oral semaglutide 25 mg in the OASIS 4 trial?

Accepted Answer

Novo Nordisk reported that once-daily oral semaglutide 25 mg achieved approximately 17% mean weight loss in OASIS 4, with about one in three participants reaching ≥20% weight loss.

Question 5

What did Hargreaves Lansdown's May earnings preview say about Novo Nordisk's early‑May results?

Accepted Answer

Hargreaves Lansdown's May earnings preview highlighted the recurring themes mentioned above and flagged Novo Nordisk's early‑May results as a key readthrough for whether recent momentum can be sustained.

Question 6

What did Novo Nordisk do with its Parkinson's cell therapy program?

Accepted Answer

Novo Nordisk sold the Parkinson's cell therapy program to Cellular Intelligence, divesting a non-core, high-cost early-stage biologic while retaining optionality via a minority equity position and contingent payments.

Timeline

Novo Nordisk launches Wegovypill in the UAE

Novo Nordisk study finds two in five high‑risk cardiovascular patients have persistent inflammation

Health & Bio Today: Adaptix wins CE mark for Ortho350, Physiomics, IXICO, Novo Nordisk

The Premarket Brief: Marston's reaffirms FY2026 guidance on margin gains, Angling Direct, Greggs, Wickes, Novo Nordisk, Wizz Air

More in Healthcare

Hansoh Phase III win bolsters GSK's global case for Ris-Rez in lung cancer

Genedrive's personalised medicine receives Parliament boost

Health & Bio Today: AstraZeneca ATTR-CM trial fails primary endpoint, Avacta, Spire Healthcare, Smith+Nephew

Toscafund gets four more weeks to move on Spire Healthcare bid

Avacta settles £3.67m convertible bond payment in cash

AstraZeneca and Ionis ATTR-CM trial fails primary endpoint

Smith and Nephew backs first German clinical consensus on single-use wound therapy

OKYO Pharma accelerates urcosimod into Phase 3 after FDA validates trial design

Small Caps Today: Quadrise, Union Jack Oil, Galantas Gold, Itaconix, EDX Medical . . .

Physiomics wins contracts across two service lines

Segro doubles new rent secured in first half as development pipeline hits record

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer